Predictive Factors and Value of ypN plus after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer

被引:3
作者
Fukada, Ippei [1 ]
Araki, Kazuhiro [1 ]
Kobayashi, Kokoro [1 ]
Shibayama, Tomoko [1 ]
Takahashi, Shunji [2 ]
Horii, Rie [3 ]
Akiyama, Futoshi [4 ]
Iwase, Takuji [5 ]
Ohno, Shinji [6 ]
Hatake, Kiyohiko [7 ]
Hozumi, Yasuo [8 ]
Sata, Naohiro [9 ]
Ito, Yoshinori [1 ]
机构
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Breast Med Oncol, Tokyo, Japan
[2] Japanese Fdn Canc Res, Canc Inst Hosp, Med Oncol, Tokyo, Japan
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Div Pathol, Tokyo, Japan
[4] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Tokyo, Japan
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Breast Oncol Ctr, Breast Surg Oncol, Tokyo, Japan
[6] Japanese Fdn Canc Res, Canc Inst Hosp, Breast Oncol Ctr, Tokyo, Japan
[7] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol & Oncol, Tokyo, Japan
[8] Ibaraki Cent Hosp, Dept Surg, Ibaraki, Japan
[9] Jichi Med Univ, Dept Gastrointestinal Surg, Shimotsuke, Tochigi, Japan
来源
PLOS ONE | 2016年 / 11卷 / 09期
关键词
INTERNATIONAL EXPERT CONSENSUS; PREOPERATIVE CHEMOTHERAPY; PRIMARY THERAPY; RECOMMENDATIONS; PACLITAXEL; HIGHLIGHTS; DOCETAXEL; SUBTYPES; UPDATE; TRIAL;
D O I
10.1371/journal.pone.0162616
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Pathological complete response (pCR) with neoadjuvant chemotherapy (NAC) has been regarded as a surrogate endpoint for disease-free survival (DFS) and overall survival (OS) of patients with breast cancer. No consensus regarding the definition of pCR has been established; there are several definitions according to a variety of classifications. Eradication of cancer cells in both breast and lymph nodes has been better associated with improved prognosis than in the breast alone. Even in patients diagnosed as having clinically node-negative cancer before NAC, postoperative pathological examination often shows axillary lymph node metastases. Patients and Methods Of the 771 patients with breast cancer who underwent NAC in the Cancer Institute Hospital between January 2000 and May 2009, 146 patients preoperatively diagnosed as having node-negative breast cancer were retrospectively evaluated. We have made the definition of clinically lymph node-negative (N0) as follows: first, ultrasonography before NAC did not show any lymphadenopathy. Second, a cytological procedure confirmed negative study for each patient when ultrasonography suggested lymphadenopathy. Results The median observation period was 79.7 months, and the median age of the subjects was 51 years. Pathological examination at the time of the surgery showed lymph node metastases (ypN+) in 46 patients (31.5%). Histological therapeutic effects revealed ypT0/is in 9 patients (6.2%) and ypTinv in 137 (93.8%). Multivariate analysis demonstrated that younger age (49>), large tumor size, NG3, and ypN+ were significant poor prognostic factors for DFS (p = 0.020, p = 0.008, P = 0.022 and p = 0.010, respectively). Moreover, ypN+ was the only significant poor prognostic factor for OS (p = 0.022). The predictive factors of ypN+ in clinically lymph node-negative breast cancer were ypTinv (p = 0.036) and the luminal type (HR+ and HER2-) (p = 0.029). Conclusion The prognosis of clinically lymph node negative breast cancer depended on ypN+, which was associated with ypTinv and luminal subtype.
引用
收藏
页数:13
相关论文
共 22 条
  • [1] Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer:: A systematic review
    Alvarez, S
    Añorbe, E
    Alcorta, P
    López, F
    Alonso, I
    Cortés, J
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2006, 186 (05) : 1342 - 1348
  • [2] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
    Cortazar, Patricia
    Zhang, Lijun
    Untch, Michael
    Mehta, Keyur
    Costantino, Joseph P.
    Wolmark, Norman
    Bonnefoi, Herve
    Cameron, David
    Gianni, Luca
    Valagussa, Pinuccia
    Swain, Sandra M.
    Prowell, Tatiana
    Loibl, Sibylle
    Wickerham, D. Lawrence
    Bogaerts, Jan
    Baselga, Jose
    Perou, Charles
    Blumenthal, Gideon
    Blohmer, Jens
    Mamounas, Eleftherios P.
    Bergh, Jonas
    Semiglazov, Vladimir
    Justice, Robert
    Eidtmann, Holger
    Paik, Soonmyung
    Piccart, Martine
    Sridhara, Rajeshwari
    Fasching, Peter A.
    Slaets, Leen
    Tang, Shenghui
    Gerber, Bernd
    Geyer, Charles E., Jr.
    Pazdur, Richard
    Ditsch, Nina
    Rastogi, Priya
    Eiermann, Wolfgang
    von Minckwitz, Gunter
    [J]. LANCET, 2014, 384 (9938) : 164 - 172
  • [3] Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer
    Deurloo, EE
    Tanis, PJ
    Gilhuijs, KGA
    Muller, SH
    Kröger, R
    Peterse, JL
    Rutgers, EJT
    Olmos, RV
    Kool, LJS
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (08) : 1068 - 1073
  • [4] Tumor size and survival in breast cancer-a reappraisal
    Foulkes, William D.
    Reis-Filho, Jorge S.
    Narod, Steven A.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (06) : 348 - 353
  • [5] Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
    Goldhirsch, A.
    Winer, E. P.
    Coates, A. S.
    Gelber, R. D.
    Piccart-Gebhart, M.
    Thuerlimann, B.
    Senn, H. -J.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (09) : 2206 - 2223
  • [6] Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
    Goldhirsch, A.
    Wood, W. C.
    Coates, A. S.
    Gelber, R. D.
    Thuerlimann, B.
    Senn, H. -J.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (08) : 1736 - 1747
  • [7] Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    Green, MC
    Buzdar, AU
    Smith, T
    Ibrahim, NK
    Valero, V
    Rosales, MF
    Cristofanilli, M
    Booser, DJ
    Pusztai, L
    Rivera, E
    Theriault, RL
    Carter, C
    Frye, D
    Hunt, KK
    Symmans, WF
    Strom, EA
    Sahin, AA
    Sikov, W
    Hortobagyi, GN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5983 - 5992
  • [8] HER2 and response to paclitaxel in node-positive breast cancer
    Hayes, Daniel F.
    Thor, Ann D.
    Dressler, Lynn G.
    Weaver, Donald
    Edgerton, Susan
    Cowan, David
    Broadwater, Gloria
    Goldstein, Lori J.
    Martino, Silvana
    Ingle, James N.
    Henderson, I. Craig
    Norton, Larry
    Winer, Eric P.
    Hudis, Clifford A.
    Ellis, Matthew J.
    Berry, Donald A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (15) : 1496 - 1506
  • [9] Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
    Hugh, Judith
    Hanson, John
    Cheang, Maggie Chon U.
    Nielsen, Torsten O.
    Perou, Charles M.
    Dumontet, Charles
    Reed, John
    Krajewska, Maryla
    Treilleux, Isabelle
    Rupin, Matthieu
    Magherini, Emmanuelle
    Mackey, John
    Martin, Miguel
    Vogel, Charles
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1168 - 1176
  • [10] Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
    Kaufmann, M
    Hortobagyi, GN
    Goldhirsch, A
    Scholl, S
    Makris, A
    Valagussa, P
    Blohmer, JU
    Eiermann, W
    Jackesz, R
    Jonat, W
    Lebeau, A
    Loibl, S
    Miller, W
    Seeber, S
    Semiglazov, V
    Smith, R
    Souchon, R
    Stearns, V
    Untch, M
    von Minckwitz, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) : 1940 - 1949